



MITHRA SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR THE COMMERCIALIZATION OF MYRING™ IN CHILE WITH LABORATORIO PASTEUR

Liège, Belgium, 27 September 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women's Health, is pleased to announce the finalization and signature of the contract with Laboratorio Pasteur S.A., a Chilean pharmaceutical company also devoted to women's health, for an exclusive License and Supply Agreement (LSA) to commercialize Myring™¹ in Chile.

Under the terms of the 10-year contract, Mithra will be eligible for upfront and milestone payments, Minimal Annual Quantities (MAQ) and further sales-related royalties. Moreover, Mithra will produce Myring™ for the Chilean market at its CDMO facility in Belgium.

The Chilean contraceptive market is worth approximately EUR 92 million a year², with the vaginal contraceptive ring market accounting for EUR 5.8 million³. The contraceptive ring market is fast-growing in Chile, having grown 18% between 2016 and 2017.

Laboratorio Pasteur SA is a pharmaceutical manufacturing company with more than 85 years of experience in the Chilean health care market. It is headquartered in Santiago de Chile, with a manufacturing plant in Concepcion. The company recorded 2017 sales of USD 17M, with double digit growth over the market increase, and has a large distribution network and marketing infrastructure in a number of Latin American countries and international markets. Its specialties include paediatrics, gynaecology, bronchopulmonary and general medicine.

François Fornieri, CEO of Mithra, commented: *"We are extremely pleased to have finalized the contract with Laboratorio Pasteur for the commercialization of Myring™ in Chile. Laboratorio Pasteur's long history in the Chilean market makes them an excellent partner for us in this territory. This contract is yet another step forward in Mithra's strategy to identify and collaborate with Women's Health leaders around the world."*

For more information, please contact:

Investor Relations & Press

François Fornieri (CEO): +32 4 349 28 22

Jean-Manuel Fontaine (PRO): +32 (0)476 96 54 59

investorrelations@mithra.com

¹ Myring™ will be marketed under a different name by Laboratorio Pasteur SA

² IQVIA (IMS) Q3 2017; CAGR +3% (2013-2017)

³ IQVIA (IMS) Q3 2017; CAGR +4% (2013-2017)

About Myring™

Myring™ is developed to be a generic of Nuvaring® vaginal ring. Nuvaring®'s patent expired in April 2018 both in the US and in EU. Myring™ (etonogestrel/ethinyl estradiol vaginal ring) is a nonbiodegradable, flexible, transparent, combination contraceptive vaginal ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It is made of ethylene vinylacetate copolymers, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. When placed in the vagina, each ring releases, in line with the originator (Nuvaring®), on average 0.120 mg/day of etonogestrel and 0.015 mg/day of ethinyl estradiol over a three-week period of use. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed.

About Laboratorio Pasteur SA

Laboratorio Pasteur SA is a pharmaceutical manufacturing company with more than 85 years of experience in the Chilean health care market. It is headquartered in Santiago de Chile, with a manufacturing plant in Concepcion. The company recorded 2017 sales of USD 17m, with double digit growth over the market increase, and has a large distribution network and marketing infrastructure in a number of Latin American countries and international markets. Its specialties include paediatrics, gynaecology, bronchopulmonary and general medicine.

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com